EVP, CFO & CBO · Dianthus Therapeutics, Inc. /DE/ · Common Stock
Side
SELL
Value
$196K
Shares
2,366
Price
$82.84
Executed
Mar 31, 2026
Disclosed
Apr 1, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Mar 31 executedApr 1, 2026 disclosed
DNTH · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering+5 / 15
1 other actor traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Savitz Ryan filed this Form 4 reporting a open-market sale of DNTH on Mar 31, 2026. It became public on Apr 1, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
EVP, CFO & CBO
Savitz Ryancik:0001992324
Issuer
Dianthus Therapeutics, Inc. /DE/cik:0001690585
Revision history · 0
No field has changed since this record was first ingested.
